[article] 
inAutism Research > 15-11 (November 2022) . - p.2192-2199

Titre :	Risk of exposure to prescription opioids in children and adolescents with autism spectrum disorder: A nationwide longitudinal study
Type de document :	Texte imprimé et/ou numérique
Auteurs :	Ju-Wei HSU, Auteur ; Shih-Jen TSAI, Auteur ; Ya-Mei BAI, Auteur ; Kai-Lin HUANG, Auteur ; Tung-Ping SU, Auteur ; Tzeng-Ji CHEN, Auteur ; Mu-Hong CHEN, Auteur
Article en page(s) :	p.2192-2199
Langues :	Anglais (eng)
Mots-clés :	Child  Adolescent  Humans  Autism Spectrum Disorder/drug therapy  Longitudinal Studies  Analgesics, Opioid/adverse effects  Chronic Pain/complications/drug therapy  Prescriptions  autism  medical conditions  mental disorders  prescription opioids
Index. décimale :	PER Périodiques
Résumé :	Whether children and adolescents with autism spectrum disorder (ASD) are more likely to be exposed to prescription opioids than others remains unknown. The Taiwan National Health Insurance Research Database was employed, and 14,849 children and adolescents with ASD and 148,490 age- and sex-matched non-ASD controls were enrolled between 2001 and 2009 and followed up till the end of 2011. Those exposed to prescription opioids during the follow-up period were identified. Patients with ASD were more likely to be exposed to prescription opioids (hazard ratio [HR]: 4.95, 95% confidence interval [CI]: 4.50-5.45), including intravenous or intramuscular opioids (HR: 5.80, 95% CI: 5.23-6.43) and oral or transcutaneous opioids (HR: 2.32, 95% CI: 1.87-2.89), than were non-ASD controls. Furthermore, the ASD cohort had the increased likelihood of cumulative exposure of>14 days (HR: 6.19, 95% CI: 4.91-7.79) and>30 days (HR: 7.17, 95% CI: 5.19-9.90) to prescription opioids compared with the control cohort. ASD was a risk factor for exposure to prescription opioids. Close monitoring of prescription opioid use is necessary for at-risk children and adolescents with ASD, such as those having with or chronic pain. We found that patients with ASD were more likely to be exposed to prescription opioids, including intravenous or intramuscular opioids and oral or transcutaneous opioids, than were non-ASD controls. We suggest that close monitoring of prescription opioid use is necessary for at-risk children and adolescents with ASD, such as those having with or chronic pain.
En ligne :	http://dx.doi.org/10.1002/aur.2806
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=488

[article] Risk of exposure to prescription opioids in children and adolescents with autism spectrum disorder: A nationwide longitudinal study [Texte imprimé et/ou numérique] / Ju-Wei HSU, Auteur ; Shih-Jen TSAI, Auteur ; Ya-Mei BAI, Auteur ; Kai-Lin HUANG, Auteur ; Tung-Ping SU, Auteur ; Tzeng-Ji CHEN, Auteur ; Mu-Hong CHEN, Auteur . - p.2192-2199.
Langues : Anglais (eng)
in Autism Research > 15-11 (November 2022) . - p.2192-2199

Mots-clés :	Child  Adolescent  Humans  Autism Spectrum Disorder/drug therapy  Longitudinal Studies  Analgesics, Opioid/adverse effects  Chronic Pain/complications/drug therapy  Prescriptions  autism  medical conditions  mental disorders  prescription opioids
Index. décimale :	PER Périodiques
Résumé :	Whether children and adolescents with autism spectrum disorder (ASD) are more likely to be exposed to prescription opioids than others remains unknown. The Taiwan National Health Insurance Research Database was employed, and 14,849 children and adolescents with ASD and 148,490 age- and sex-matched non-ASD controls were enrolled between 2001 and 2009 and followed up till the end of 2011. Those exposed to prescription opioids during the follow-up period were identified. Patients with ASD were more likely to be exposed to prescription opioids (hazard ratio [HR]: 4.95, 95% confidence interval [CI]: 4.50-5.45), including intravenous or intramuscular opioids (HR: 5.80, 95% CI: 5.23-6.43) and oral or transcutaneous opioids (HR: 2.32, 95% CI: 1.87-2.89), than were non-ASD controls. Furthermore, the ASD cohort had the increased likelihood of cumulative exposure of>14 days (HR: 6.19, 95% CI: 4.91-7.79) and>30 days (HR: 7.17, 95% CI: 5.19-9.90) to prescription opioids compared with the control cohort. ASD was a risk factor for exposure to prescription opioids. Close monitoring of prescription opioid use is necessary for at-risk children and adolescents with ASD, such as those having with or chronic pain. We found that patients with ASD were more likely to be exposed to prescription opioids, including intravenous or intramuscular opioids and oral or transcutaneous opioids, than were non-ASD controls. We suggest that close monitoring of prescription opioid use is necessary for at-risk children and adolescents with ASD, such as those having with or chronic pain.
En ligne :	http://dx.doi.org/10.1002/aur.2806
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=488